Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Daiichi Sankyo (3 DXd ADC Oncology Programs) by Year
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Commercialization / SG&A expense sharing ($M) ($M)
Merck Daiichi Sankyo (3 DXd ADC Oncology Programs): $28M in FY2025, up 7.7% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Daiichi Sankyo (3 DXd ADC Oncology Programs) — Commercialization / SG&A expense sharing ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 28 | +7.7% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 26 | +766.7% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 3 | – | Form 10-K (filed 2026-02-24) ↗ |
Cite this data
StockData. (2026). Merck Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-daiichisankyo-sga
See every metric in the Merck KPI table. Data updated Oct 26, 2026.